Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma.

Autor: Kropivsek K; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.; Swiss Institute of Bioinformatics, Lausanne, Switzerland., Kachel P; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Goetze S; Swiss Institute of Bioinformatics, Lausanne, Switzerland.; Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.; Swiss Multi-Omics Center, PHRT-CPAC, ETH Zurich, Zurich, Switzerland., Wegmann R; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.; Swiss Institute of Bioinformatics, Lausanne, Switzerland., Festl Y; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.; Swiss Institute of Bioinformatics, Lausanne, Switzerland., Severin Y; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.; Swiss Institute of Bioinformatics, Lausanne, Switzerland., Hale BD; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.; Swiss Institute of Bioinformatics, Lausanne, Switzerland., Mena J; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.; Swiss Institute of Bioinformatics, Lausanne, Switzerland., van Drogen A; Swiss Institute of Bioinformatics, Lausanne, Switzerland.; Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.; Swiss Multi-Omics Center, PHRT-CPAC, ETH Zurich, Zurich, Switzerland., Dietliker N; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Tchinda J; Pediatric Oncology, Children's Research Centre, University Children's Hospital Zurich, Zurich, Switzerland., Wollscheid B; Swiss Institute of Bioinformatics, Lausanne, Switzerland.; Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.; Swiss Multi-Omics Center, PHRT-CPAC, ETH Zurich, Zurich, Switzerland., Manz MG; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.; Comprehensive Cancer Center Zurich (CCCZ), Zurich, Switzerland., Snijder B; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland. snijder@imsb.biol.ethz.ch.; Swiss Institute of Bioinformatics, Lausanne, Switzerland. snijder@imsb.biol.ethz.ch.; Comprehensive Cancer Center Zurich (CCCZ), Zurich, Switzerland. snijder@imsb.biol.ethz.ch.

Publikováno v: Nature cancer [Nat Cancer] 2023 May; Vol. 4 (5), pp. 734-753. Date of Electronic Publication: 2023 Apr 20.

A novel dual-cytokine-antibody fusion protein for the treatment of CD38-positive malignancies.

Autor: De Luca R; Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Vladimir-Prelog-Weg 4, Zürich, Switzerland., Kachel P; Department of Hematology, University Hospital and University of Zurich, Rämistrasse 100, Zürich, Switzerland., Kropivsek K; Department of Biology, Institute of Molecular System Biology, Swiss Federal Institute of Technology (ETH Zürich), Auguste-Piccard-Hof 1, Zurich, Switzerland., Snijder B; Department of Biology, Institute of Molecular System Biology, Swiss Federal Institute of Technology (ETH Zürich), Auguste-Piccard-Hof 1, Zurich, Switzerland., Manz MG; Department of Hematology, University Hospital and University of Zurich, Rämistrasse 100, Zürich, Switzerland., Neri D; Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Vladimir-Prelog-Weg 4, Zürich, Switzerland.

Publikováno v: Protein engineering, design & selection : PEDS [Protein Eng Des Sel] 2018 May 01; Vol. 31 (5), pp. 173-179.

Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia.

Autor: Wegmann, Rebekka, Bonilla, Ximena, Casanova, Ruben, Chevrier, Stéphane, Coelho, Ricardo, Esposito, Cinzia, Ficek-Pascual, Joanna, Goetze, Sandra, Gut, Gabriele, Jacob, Francis, Jacobs, Andrea, Kuipers, Jack, Lischetti, Ulrike, Mena, Julien, Milani, Emanuela S., Prummer, Michael, Del Castillo, Jacobo Sarabia, Singer, Franziska, Sivapatham, Sujana, Toussaint, Nora C.

Publikováno v: Nature Communications; 10/30/2024, Vol. 15 Issue 1, p1-18, 18p

Molecular and functional landscape of malignant serous effusions for precision oncology.

Autor: Wegmann, Rebekka, Bankel, Lorenz, Festl, Yasmin, Lau, Kate, Lee, Sohyon, Arnold, Fabian, Cappelletti, Valentina, Fehr, Aaron, Picotti, Paola, Dedes, Konstantin J., Franzen, Daniel, Lenggenhager, Daniela, Bode, Peter K., Zoche, Martin, Moch, Holger, Britschgi, Christian, Snijder, Berend

Publikováno v: Nature Communications; 10/2/2024, Vol. 15 Issue 1, p1-21, 21p

An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions.

Autor: Prodi, Eleonora^1,2 (AUTHOR), Comacchio, Claudia¹ (AUTHOR), Gilardoni, Ettore¹ (AUTHOR), Di Nitto, Cesare¹ (AUTHOR), Puca, Emanuele¹ (AUTHOR), Neri, Dario³ (AUTHOR), De Luca, Roberto¹ (AUTHOR) roberto.deluca@philochem.ch

Publikováno v: Antibodies (2073-4468). Jun2023, Vol. 12 Issue 2, p29. 13p.